Linked Life Data

3351336

Source:http://linkedlifedata.com/resource/pubmed/id/3351336

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3351336rdf:typepubmed:Citationlld:pubmed
pubmed-article:3351336lifeskim:mentionsumls-concept:C0038317lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C1522496lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0678896lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0017110lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0037813lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0332237lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C1522168lld:lifeskim
pubmed-article:3351336lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:3351336pubmed:issue4lld:pubmed
pubmed-article:3351336pubmed:dateCreated1988-4-27lld:pubmed
pubmed-article:3351336pubmed:abstractTextWe evaluated 38 males who had psoriasis vulgaris for evidence of hypothalamus-pituitary-adrenal axis suppression (HPAS) during treatment with superpotent topical glucocorticosteroids. All men were treated with 49 g per week of either Betamethasone Diproprionate in an optimized vehicle or Clobetasol Proprionate ointment. Three methods used to assess HPAS were compared. Classic 8 a.m. plasma cortisol measurements, urinary-free cortisol, and 17-hydroxycorticosteroid determinations and gas chromatograph-mass spectrometry (GCMS) quantitation of urinary cortisol metabolites were compared. Values for all methods were obtained just prior to therapy and at days 4, 7, 14, and 21 during therapy and at day 28 after treatment was stopped for 7 d. Plasma cortisol measurements correlated well with other measures of HPAS. GCMS determination of urinary cortisol metabolites was slightly more sensitive at detecting HPAS than the other two methods. Persistent HPAS after day 7 was only appreciated by GCMS. Urinary-free cortisol and 17-hydroxycortisol was the least sensitive of the three methods. Analysis of urinary cortisol metabolites by GCMS may be most useful in the monitoring of HPAS resulting from use of topical glucocorticosteroid preparations.lld:pubmed
pubmed-article:3351336pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3351336pubmed:languageenglld:pubmed
pubmed-article:3351336pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3351336pubmed:citationSubsetIMlld:pubmed
pubmed-article:3351336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3351336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3351336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3351336pubmed:statusMEDLINElld:pubmed
pubmed-article:3351336pubmed:monthAprlld:pubmed
pubmed-article:3351336pubmed:issn0022-202Xlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:SchwabHHlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:FennesseyP...lld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:MorelloDDlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:WestonW LWLlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:HarrisonL MLMlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:GotlinRRlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:SamsomBBlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:MooneyJJlld:pubmed
pubmed-article:3351336pubmed:authorpubmed-author:HuffLLlld:pubmed
pubmed-article:3351336pubmed:issnTypePrintlld:pubmed
pubmed-article:3351336pubmed:volume90lld:pubmed
pubmed-article:3351336pubmed:ownerNLMlld:pubmed
pubmed-article:3351336pubmed:authorsCompleteYlld:pubmed
pubmed-article:3351336pubmed:pagination532-5lld:pubmed
pubmed-article:3351336pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:meshHeadingpubmed-meshheading:3351336-...lld:pubmed
pubmed-article:3351336pubmed:year1988lld:pubmed
pubmed-article:3351336pubmed:articleTitleComparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry.lld:pubmed
pubmed-article:3351336pubmed:affiliationDepartment of Dermatology, Pharmacology, and Pediatrics, University of Colorado School of Medicine, Denver 80262.lld:pubmed
pubmed-article:3351336pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3351336pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3351336pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3351336pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3351336pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3351336pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3351336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3351336lld:pubmed